Der Klinikarzt 2003; 32(10): 346-349
DOI: 10.1055/s-2003-43280
In diesem Monat

© Georg Thieme Verlag Stuttgart · New York

Hypertonie und Progression von Nierenerkrankungen - Konsequente Blutdruckeinstellung ist von essenzieller Bedeutung

Hypertension and Progression of Renal Disease - Rigorous Control of Blood Pressure is EssentialG.R. Hetzel1
  • 1Klinik für Nephrologie und Rheumatologie, Universitätsklinikum Düsseldorf (Direktor: Prof. Dr. B. Grabensee)
Further Information

Publication History

Publication Date:
31 October 2003 (online)

Zusammenfassung

Bei nahezu allen renoparenchymatösen Erkrankungen, die zur chronischen Niereninsuffizienz führen, kann sich im Verlauf der Erkrankung eine arterielle Hypertonie multifaktorieller Genese entwickeln. Um die Progression einer chronischen bis hin zur terminalen Niereninsuffizienz zu verzögern, wird heute eine frühe und konsequente Einstellung des Bluthochdrucks gefordert (Zielblutdruckwert: < 130/80; bei Proteinurie über 1 g/Tag: < 125/75). Damit lässt sich aber nicht nur die Nierenfunktion langfristig erhalten, auch das kardiovaskuläre Risiko - das sich bei Patienten mit chronischer Niereninsuffizienz drastisch erhöht - ist so signifikant zu reduzieren. Je nach Grunderkrankung der Patienten werden heute ACE-Hemmer bzw. Angiotensin-Rezeptor-Antagonisten zur First-line-Therapie empfohlen. Denn beide Substanzklassen greifen direkt in das Renin-Angiotensin-Aldosteron-System (RAAS) ein, das bei Niereninsuffizienten inadäquat stimuliert ist. Sie regulieren nicht nur den Bluthochdruck, sondern scheinen zudem unabhängige renoprotektive Effekte aufzuweisen.

Summary

In virtually all diseases affecting the renal parenchyma that lead to chronic renal failure, arterial hypertension of multifactorial genesis may subsequently develop. With the aim of delaying progression of a chronic disease to terminal renal failure, early and rigorous control of hypertension is mandatory (target:< 130/80; in proteinurea > 1 g/day:< 125/75). With this approach not only can renal function be preserved over the longer term, but also the cardiovascular risk - which is dramatically elevated in patients with chronic renal insufficiency - can be significantly reduced. Depending on the underlying disease, ACE-inhibitors or angiotensin receptor antagonists are currently first-line treatment, since both of these classes of drug act directly on the renin-angiotensin-aldosterone system (RAAS), which is inappropriately stimulated in renal failure. Not only do these substances regulate the high blood pressure, but also appear to have independent renoprotective effects.

Literatur

  • 1 Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney.  Am J Physiol. 1987;  252 1003-1010
  • 2 Borch-Johnsen K, Andersen PK, Hostetter TH. The effect of proteinuriea on relative mortality in type 1 (insulin-dependent) diabetes mellitus.  Diabetologia. 1985;  28 590-596
  • 3 Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.  N Engl J Med. 1982;  307 652-659
  • 4 Brenner BM, Cooper ME, De D Zeeuw. et al. . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2001;  345 861-869
  • 5 Brown MJ, Palmer CR, Castaigne A. et al. . Morbidity and mortality in patients randomized to double-blind treatment with a long acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).  Lancet. 2000;  356 366-372
  • 6 Donadelli R, Abbate M, Zanchi C. et al. . Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation.  Am J Kidney Dis. 2000;  36 1226-1241
  • 7 Estacio RO, Jeffers BW, Gifford N. et al. . Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.  Diabetes Care. 2000;  23 54-64
  • 8 Gansevoort RT, Sluiter WJ, Hemmelder MH. et al. . Antiproteinuric effect of blood-pressure lowering agents: A meta-analysis of comparative trials.  Nephrol Dial Transplant. 1995;  10 1963-1974
  • 9 Gerstein HC, Mann JFE, Yi Q. HOPE Study Investigators . Albuminuria, and risk of cardiovascular events, death and heart failure in diabetic and non-diabetic individuals.  JAMA. 2001;  286 421-426
  • 10 Jafar TH, Schmid CH, Landa M. et al. . Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis on patient level data.  Ann Intern Med. 2001;  135 73-87
  • 11 Kasiske BL, Kalil RS, Ma JZ. et al. . Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis.  Ann Intern Med. 1993;  118 129-138
  • 12 Klahr S, Levey AS, Beck GJ. et al. . The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: the Modification of Diet in Renal Disease Study.  N Engl J Med. 1994;  330 877-884
  • 13 Lewis EJ, Hunsicker LG, Bain RP, Rohde ED. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy.  N Engl J Med. 1993;  329 1456-1462
  • 14 Lewis EJ, Hunsicker LG, Clarke WR. et al. . Renoprotective effect of the angiotensin-receptor-antagonist irbesartan in patients with nephropathy due to type 2 diabetes.  N Engl J Med. 2001;  345 851-860
  • 15 Lindholm LH, Ibsen H, Dahlöf B. et al. . Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.  Lancet. 2002;  359 1004-1010
  • 16 Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials.  J Hypertens. 2002;  20 1461-1464
  • 17 Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.  Scand J Lab Invest. 1976;  36 383-388
  • 18 Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas.  Diabetologia. 1999;  263-285
  • 19 Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.  Lancet. 1983;  1 1175-1179
  • 20 Peterson JC, Adler S, Burkart JM. Blood-pressure control, proteinuria and the progression of chronic renal disease: The Modification of Diet in Renal Disease Study.  Ann Intern Med. 1995;  123 754-762
  • 21 Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population.  Endocrinol Metab Clin North Am. 1997;  26 125-144
  • 22 Remuzzi A, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression.  Kidney Int. 1997;  51 2-15
  • 23 Schrier RW, Estacio RO, Esler A. et al. . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke.  Kidney Int. 2002;  61 1086-1097
  • 24 Shemin D, Dworkin LD. Sodium balance in renal failure.  Curr Opin Nephrol Hypertens. 1997;  6 128-132
  • 25 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic.  JAMA. 2002;  288 2981-2997
  • 26 UK Prospective Diabetes Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.  BMJ. 1998;  317 713-720
  • 27 Walls John. Relationship between proteinuria and progressive renal disease.  Am J Kidney Dis. 2001;  37 13-16
  • 28 Weidmann P, Schneider M, Böhlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis.  Nephrol Dial Transplant. 1995;  10 39-45
  • 29 Wright JT, Bakris G, Greene T. et al. . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease.  JAMA. 2002;  288 2421-2431
  • 30 Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials.  J Hypertens. 2002;  20 2099-2110

1 heart outcomes prevention study

2 modification of diet in renal disease

3 antihypertensive and lipid lowering treatment to prevent heart attack trial

4 african-american study of kidney disease

Anschrift des Verfassers

PD Dr. Gerd Rüdiger Hetzel

Klinik für Nephrologie und Rheumatologie

Universitätsklinikum Düsseldorf

Moorenstr. 5

40225 Düsseldorf

    >